Mangala Gunatilake

Mangala Gunatilake

Auto-generated profile, based on publicly available information

Mangala Gunatilake

University of Colombo

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Animal Models and Experimental Medicine
Verified
Journal Article
Open access
PDF file
SDShehani L. Delwatta
Shehani L. Delwatta
MGMangala Gunatilake
Mangala Gunatilake
VBVera Baumans
Vera Baumans
MSMelanie D. Seneviratne
Melanie D. Seneviratne
MDManjula L. B. Dissanayaka
Manjula L. B. Dissanayaka
PWPrasad B. Walpola
Prasad B. Walpola
Background: Lack of available reference values in a research setting under local conditions can be a drawback for beginners, as the accuracy of data from control samples cannot be checked at the beginning of a research project. This affects comparisons with data from test samples. To avoid these complications in their research projects, beginners tend to have a greater number of animals in the control group compared to test groups in order to have control group measurements within 2 SD s of the mean. Methods: As non‐availability of reference values was a long‐felt need, the described project was conducted in order to establish a reference database for selected haematological, biochemical and physiological parameters using apparently healthy Sprague‐Dawley rats bred in the Animal House of Faculty of Medicine, University of Colombo (UCFM). Results: Differences in mean values of packed cell volume ( PCV ), mean corpuscular volume ( MCV ) and mean corpuscular hemoglobin concentration ( MCHC ), serum creatinine and blood glucose levels between the two genders were statistically significant. Lipid profile measurements did not differ significantly between genders, but mean and median values of triglycerides ( TG ) between male and female rats showed a difference of more than 10 mg/dL. The liver enzymes alkaline phosphatase ( AP ) and aspartate aminotransferase ( AST ) were also statistically significantly different between sexes. Despite wide variation in mean alanine aminotransferase ( ALT ) between sexes, the difference was not statistically significant. Conclusion: The findings of this project should support to a certain extent the “Reduction” aspect of the 3Rs concept of Russell and Burch by reducing the number of Sprague‐Dawley rats used in future research projects at UCFM .

18 May 2017 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
RPR.M.S. Pimburage
R.M.S. Pimburage
MGM. Gunatilake
M. Gunatilake
OWO. Wimalaratne
O. Wimalaratne
ABA. Balasuriya
A. Balasuriya
KPK.A.D.N. Perera
K.A.D.N. Perera
Mass vaccination of dogs is considered fundamental for national rabies control programmes in Sri Lanka, as dog is the main reservoir and transmitter of the disease. Dogs were followed to determine the sero-prevalence of antibodies to the rabies virus. Altogether 510 previously vaccinated and unvaccinated dogs with owners (domestic dogs) and dogs without owners (stray dogs) of the local guard dog breed in different age groups recruited from Kalutara District, Sri Lanka. The dogs were vaccinated with a monovalent inactivated vaccine intramuscularly and serum antibody titres on days 0, 30, 180 and 360 were determined by the Rapid Fluorescent Focus Inhibition Test (RFFIT). The results indicated, a single dose of anti-rabies vaccination fails to generate a protective level of immunity (0.5 IU/ml) which lasts until 1 year in 40.42% of dogs without owners and 57.14% of previously unvaccinated juvenile (age: 3 months to 1 year) dogs with owners. More than one vaccination would help to maintain antibody titres above the protective level in the majority of dogs. The pattern of antibody titre development in annually vaccinated and irregularly vaccinated (not annual) adult dogs with owners is closely similar irrespective of regularity in vaccination. Previously vaccinated animals have higher (2 IU/ml) antibody titres to begin with and have a higher antibody titre on day 360 too. They show a very good antibody titre by day 180. Unvaccinated animals start with low antibody titre and return to low titres by day 360, but have a satisfactory antibody titre by day 180. A single dose of anti-rabies vaccination is not sufficient for the maintenance of antibody titres for a period of 1 year in puppies, juvenile dogs with owners and in dogs without owners. Maternal antibodies do not provide adequate protection to puppies of previously vaccinated dams and puppies of previously unvaccinated dams. Immunity development after vaccination seems to be closely similar in both the groups of puppies.

1 January 2012 in Pharmacognosy Research
Verified
Journal Article
Open access
PDF file
MGMangala Gunatilake
Mangala Gunatilake
MLM.D.S. Lokuhetty
M.D.S. Lokuhetty
DEDilan T Edirisuriye
Dilan T Edirisuriye
MKMuditha U Kularatne
Muditha U Kularatne
NBNuwanA Bartholameuz
NuwanA Bartholameuz
ADAnand Date
Anand Date
Context: Aerva lanata is not prescribed for long-term use in Ayurveda as it is believed to produce structural changes in the urinary tract of the patients leading to renal failure. Aim: To investigate the toxic effects of Aerva lanata on the structure and function of urinary tract of a rat model (Sprague-Dawley rats). Settings and Design: An experimental study. Thirty male and thirty female healthy rats were randomly assigned to three groups (test groups 1, 2 and control) and administered dried infusion of A. lanata 25g/200ml (low dose), 100g/200ml (high dose) and distilled water respectively, for 30 days. Materials and Methods: Blood and urine were collected and creatinine was measured. Creatinine clearance (Ccr) and urine flow rate (UFR) of rats were determined to assess renal function. Kidneys, ureters, and bladders of rats were harvested for light microscopic (LM) studies. Electron microscopic (EM) studies were done on kidney tissues. Statistical Analysis Used: Difference in mean values of Ccr and UFR between test groups and the control group were compared statistically using independent T test. LM and EM findings of the two treated groups (T1 and T2) were statistically compared with the control group (C) using standard normal distribution. Results: Ccr and UFR of test groups were not significantly different from that of the control group. LM studies did not show any histological changes suggesting toxicity. EM, however showed significant ultra structural changes in proximal convoluted tubular epithelial cells of rats in the two test groups. Conclusion: Administration of dried Aerva lanata for a period of one month did not produce significant effects on renal function of rats. However administration for the same period caused significant ultra structural changes in the proximal convoluted tubular epithelial cells.

9 May 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
HRHasanthi Rathnadiwakara
Hasanthi Rathnadiwakara
MGMangala Gunatilake
Mangala Gunatilake
Alexandre ServatAlexandre Servat
Alexandre Servat
MWMarine WASNIEWSKI
Marine WASNIEWSKI
JTJean-Christophe THIBAULT
Jean-Christophe THIBAULT
FCFlorence Cliquet
Florence Cliquet
Seven brands of veterinary rabies vaccines are commercially available in Sri Lanka, but there is no established procedure to test the potency of the vaccines at the local level, especially prior to their release. The aim of this study was to test the potency of these vaccines using a mouse challenge test in collaboration with the EU/WOAH/WHO Reference Laboratory for Rabies, ANSES-Nancy, France. Based on the European Pharmacopoeia, the inactivated rabies vaccines complied with the mouse potency test if the estimated potency is ≥1.0 IU in the smallest prescribed dose. Among the eight tested vaccines, four single-dose preparations (Rabisin™, Raksharab™, Nobivac™ RL, and Nobivac™ Rabies) were compliant, with potencies of 12 IU/dose, 7.2 IU/dose, 4.4 IU/dose, and 3.4 IU/dose, respectively. Three of the single-dose preparations (Canvac™ R, Defensor™ 3, and Rabies killed vaccine) were not compliant, with potency values <1.0 IU/dose. One multidose preparation (Raksharab™ multidose) had a potency of 1.3 IU/dose, even though the test was not validated. Based on these results, it appears that some rabies vaccine batches that are currently available in the local market do not comply with the mouse potency test. Testing the vaccines’ potency before registration and release to the market appears to be an important step to allow good immunization to animals during pre-exposure vaccination programs.

1 March 2018 in Animal Models and Experimental Medicine
Verified
Journal Article
Open access
PDF file
MGMangala Gunatilake
Mangala Gunatilake
The Faculty of Medicine, University of Colombo (UCFM), is the forerunner in the laboratory animal science (LAS) field in Sri Lanka. Here laboratory animals such as rats, frogs and rabbits were used in medical education to demonstrate physiological principles in the early 1950s. The establishment of the first animal house in 1969 at UCFM better facilitated the use of laboratory animals in medical education and research. By 2006, lack of ethical guide lines was an issue and a set of ethical guidelines was developed and published in 2009, which today are followed by researchers and reviewers in many universities and research institutions in the country. With this development, there was a need for an organized system of education for the LAS discipline. This was fulfilled by conducting the first certificate course on LAS in the Asian region in 2011 in collaboration with the Utrecht University, Netherlands. The Sri Lanka Association for LAS has continued LAS education since its establishment in 2012 at UCFM by conducting workshops and short courses.

1 January 2023 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
HRHasanthi Rathnadiwakara
Hasanthi Rathnadiwakara
MGMangala Gunatilake
Mangala Gunatilake
FCFlorence Cliquet
Florence Cliquet
MWMarine WASNIEWSKI
Marine WASNIEWSKI
MTMayuri Thammitiyagodage
Mayuri Thammitiyagodage
MIMohamed Ijas
Mohamed Ijas
Rathnadiwakara H, et al. Clin Exp Vaccine Res. 2023 Apr;12(2):97-106. https://doi.org/10.7774/cevr.2023.12.2.97